Financials
Financial year 2025
INSTAPHARMA from Antwerpen, company number BE0893761760, closed financial year 2025 with a result of € 155,893 after tax. For that financial year INSTAPHARMA recorded a gross margin of € 748,463 and equity of € 219,782. Compared with financial year 2024, the result moved from € 9,292 to € 155,893. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 219,782
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 155,893
▲ € 146,600 vs 2024
Profit after tax over the fiscal year.
€ 21,583
▲ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 120,000 paid out
77 % of the profit went to the shareholders, mostly to PHARMA COVA (100 % of the shares). That is where the money ends up.
People and assets in 2025
4.6
▲ 0.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 336,301
▲ 28% vs 2024
€ 73,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,818
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.3 million
▼ 12% vs 2024
€ 137,004 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 474,093
▲ 14% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 32,602
▲ 118% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 495,877 | € 512,905 | € 526,169 | € 748,463 | ▲ 42% |
| Profit after taxes | € 87,207 | € 45,350 | € 9,292 | € 155,893 | ▲ € 146,600 |
| Equity | € 129,248 | € 174,597 | € 183,889 | € 219,782 | ▲ 20% |
| Total debts | € 3,034,787 | € 2,070,283 | € 2,337,076 | € 1,903,941 | ▼ 19% |
| Cash | € 112,350 | € 95,822 | € 19,651 | € 21,583 | ▲ 10% |
| Land & buildings | € 464,635 | € 426,231 | € 398,608 | € 383,524 | ▼ 4% |
| Retained profit | € 110,648 | € 155,997 | € 165,289 | € 201,182 | ▲ 22% |
| Dividend | € 86,000 | € 0 | € 0 | € 120,000 | |
| Bank debt | € 1,788,917 | € 1,622,110 | € 1,447,686 | € 1,269,427 | ▼ 12% |
| Balance sheet total | € 3,164,035 | € 2,244,880 | € 2,520,965 | € 2,123,723 | ▼ 16% |
| Employees (FTE) | 0 | 3.8 | 3.8 | 4.6 | ▲ 0.8 |
Key figures of INSTAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to INSTAPHARMA?
What happened at INSTAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 155,893 (▲ € 146,600 vs 2024). Source: NBB ↗
- Pharma Cova BV became a director. NBB
- New establishment in Antwerpen. KBO
- New establishment in Edegem. KBO
- Start of the company according to the CBE. KBO
In short
From € 87,207 profit in 2022 to € 155,893 profit in 2025.
Paid € 26,155 in corporate taxes since 2022.
Best year ever: 2025, with € 155,893 profit.
On average € 162,700 of value added per employee in 2025.
A new publication or filing at INSTAPHARMA? We notify you, reason included.
Follow INSTAPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMA COVA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
INSTAPHARMABehind INSTAPHARMA is Pharma Cova BV. The shares are held by PHARMA COVA (100%).
Directors
According to the 2025 annual accounts
Director · represented by Filip Cortebeeck
since 2012
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Abdijstraat 115
2020 Antwerpen
Hovestraat 7
2650 Edegem
Active since 1 January 2008
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0893.761.760
- VAT number
- BE 0893.761.760
- Registered office
- Abdijstraat 115, 2020 Antwerpen
- Names & denominations
- INSTAPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 November 2007
- Peppol
- Active · Active since 17 Jun 2025
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten
Overige niet-gespecialiseerde detailhandel
Detailhandel via postorderbedrijven of via internet